{
    "nct_id": "NCT06285422",
    "official_title": "A Phase 1 Study Evaluating SC262, a Hypoimmune, Allogeneic CD22-directed CAR T Cell Therapy, in Relapsed and/or Refractory Non-Hodgkin's Lymphoma (VIVID)",
    "inclusion_criteria": "1. Male or Female Subject aged 18-80 years at the time of signing the informed consent\n2. Histologic diagnosis of NHL (based on World Health Organization 2016 criteria) including:\n\n   * LBCL, including Diffuse Large B Cell Lymphoma (DLBCL) not otherwise specified (NOS) (including DLBCL arising from indolent lymphoma), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma (HGBCL), and Follicular Lymphoma (FL) Grade 3B\n   * FL\n   * Marginal Zone Lymphomas (MZL)\n   * Mantle Cell Lymphoma (MCL)\n3. Relapsed or refractory disease after no more than 1 prior CD19-directed CAR T cell therapy\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n5. At least 1 measurable (PET-positive) lesion per Lugano classification\n6. Life expectancy â‰¥12 Weeks\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "1. Prior CD22-directed therapy including CD22-directed CAR T cell therapy or other CD22 -directed antibody or cell therapy (e.g., Natural Killer (NK) cell)\n2. History of central nervous system (CNS) involvement of lymphoma within 1 year prior to enrollment.\n3. Autologous hematopoietic stem cell transplantation (HSCT) within 3 months before treatment with Lymphodepleting (LD) chemotherapy (or allogeneic HSCT at any time)\n4. Active autoimmune disease or any other diseases requiring immunosuppressive therapy or corticosteroid therapy (defined as >10 mg/day prednisone or equivalent)\n5. History or presence of CNS disorder, such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement, within 12 months of enrollment.",
    "miscellaneous_criteria": ""
}